Key Developments: Sequenom Inc (SQNM.OQ)

SQNM.OQ on NASDAQ Stock Exchange Global Select Market

25 Nov 2015
Change (% chg)

$0.07 (+4.12%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Sequenom Inc collaborates with University Medical Center Hamburg-eppendorf to evaluate clinical utility of liquid biopsy in colorectal cancer
Monday, 12 Oct 2015 07:00am EDT 

Sequenom Inc:Has entered into a clinical collaboration with University Medical Center Hamburg-Eppendorf in Germany.University Medical Center Hamburg-Eppendorf and Sequenom will collaborate to profile circulating cell-free tumor DNA in blood to monitor response to treatment in later stage colorectal cancer patients.  Full Article

Sequenom Inc gives H2 2015 revenue guidance; gives FY 2015 revenue guidance below analysts' estimates
Friday, 25 Sep 2015 07:00am EDT 

Sequenom Inc:Updates its revenue expectations for H2 2015 to a range between $57 million and $61 million, bringing 2015 annual revenue expectations to a range between $127 million and $131 million.Q3 2015 revenue of $35 million - Thomson Reuters I/B/E/S.Q4 2015 revenue of $35.6 million - Thomson Reuters I/B/E/S.FY 2015 revenue of $141 million - Thomson Reuters I/B/E/S.  Full Article

Sequenom Inc Announces Appointment of Dirk van den Boom as Interim President and CEO
Monday, 21 Sep 2015 07:00am EDT 

Sequenom Inc:Announced today the appointment of Dirk van den Boom, Ph.D. to the position of interim President and Chief Executive Officer. Dr. van den Boom succeeds William J. Welch following his resignation from that role, and as a director, to pursue other interests.In addition, Dr. van den Boom will continue to serve as Sequenom's Chief Scientific and Strategy Officer.  Full Article

Sequenom announces national coverage agreement with unitedhealthcare insurance company for prenatal diagnostic testing services
Thursday, 17 Sep 2015 07:00am EDT 

Sequenom:Press release - Sequenom Laboratories announces national coverage agreement with unitedhealthcare insurance company for prenatal diagnostic testing services.Says brings the number of covered lives under agreement by Sequenom laboratories' diagnostic services to more than 200 million.  Full Article

Sequenom changes in registrant’s certifying accountant - Form 8-K
Thursday, 25 Jun 2015 06:02am EDT 

Sequenom:On June 19, Company notified Ernst & Young LLP of its dismissal as the Company’s independent registered public accounting firm effective as of that date.On June 19, Company selected KPMG LLP as its new independent registered public accounting firm.  Full Article

Sequenom Inc's Sequenom Laboratories launches the HerediT UNIVERSAL Test in collaboration with Recombine
Thursday, 19 Mar 2015 05:30pm EDT 

Sequenom Laboratories:Says the launch of the HerediT UNIVERSAL carrier screening test as a service to ordering physicians.Launch of this test expands Sequenom Laboratories' reach into the universal carrier screening market.HerediT UNIVERSAL test screens for more than 250 genetic diseases by analyzing over 2,000 genetic mutations.Current options are limited to single gene testing or tests that can identify about 100 hereditary conditions.This new offering can be performed preconception or at any time during pregnancy.Sequenom Laboratories is a wholly owned subsidiary of Sequenom Inc.  Full Article

Kenneth Buechler elected Chairman of Sequenom Inc Board of Directors
Tuesday, 17 Mar 2015 07:00am EDT 

Sequenom Inc:Board elected Kenneth Buechler as Chairman of Board, effective April 1.Says Buechler succeeds Harry Hixson, Jr. who will retire from position effective March 31, after 11 years of service.  Full Article

Sequenom Inc and Cypher Genomics Inc announce development agreement
Thursday, 22 Jan 2015 07:00am EST 

Sequenom Inc and Cypher Genomics Inc:Say a development agreement for next generation noninvasive prenatal tests (NIPT).Through this agreement, Sequenom will utilize Cypher's genome interpretation technology, called Mantis, to advance analysis of clinically-relevant fetal sub-chromosomal variants detected in maternal blood.Often not detected until after birth, sub-chromosomal variants comprise greater than 50 percent of rare chromosomal abnormalities beyond the more common aneuploidies and are associated with risks of morbidity and mortality.  Full Article

Sequenom purchases noninvasive prenatal testing intellectual property from Isis Innovation
Monday, 6 Oct 2014 04:30pm EDT 

Sequenom Inc:Says the company and Isis Innovation Ltd jointly announced that Sequenom has purchased noninvasive prenatal testing intellectual property from Isis Innovation, for $14.55 mln.Under the terms of the agreement, Sequenom is now the owner of global intellectual property for noninvasive prenatal genetic diagnostic testing on paternally inherited fetal nucleic acids derived from maternal plasma or serum.Purchase price includes $3.2 mln as the final royalty payment due to Isis under the prior agreement and the waiver of $2.1 million in paid legal fees that Isis owed to Sequenom, with additional downstream payments contingent on revenues exceeding certain thresholds.  Full Article

Nicox and Sequenom announces launch of expanded access to RetnaGene test portfolio in the U.S
Thursday, 19 Jun 2014 07:00am EDT 

Sequenom Inc:Nicox and Sequenom announces that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene(tm) portfolio of laboratory-developed genetic tests in the United States (U.S.).RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual's risk for advanced age-related macular degeneration.  Full Article

Search Stocks